Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report

Miyagawa, Shigeru; Miyawaki, Takuya; Nomura, Shinsuke; Yagi, Toshiyuki; Shimada, Masahiko

doi:10.1016/j.tripleo.2003.08.005

Cited by 40 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HAE attacks are mostly triggered by trauma (especially dental trauma), medical procedures, emotional stress, menstruation, oral contraceptive use, infections, or the use of medications such as ACE inhibitors (3,4). In our report, upper respiratory track infections and menstruation seemed to trigger the attacks of HAE.…”

Section: Discussionmentioning

confidence: 47%

Effective Treatment of Hereditary Angioedema with Fresh Frozen Plasma in an Emergency Department

Pekdemir

Ersel

Aksay

et al. 2007

The Journal of Emergency Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 47%

Effective Treatment of Hereditary Angioedema with Fresh Frozen Plasma in an Emergency Department

Pekdemir

Ersel

Aksay

et al. 2007

The Journal of Emergency Medicine

View full text Add to dashboard Cite

“…No angioedema occurred, irrespective of the duration of the procedure. 71 In five additional case-series studies (n ϭ 10), 30,33,34,36,72 and 21 case reports, 42,44,45,47,58,63,[73][74][75][76][77][78][79][80][81][82][83][84][85][86][87] there were no cases of angioedema after administration of C1-INH as short-term prophylaxis. …”

Section: Preprocedural Short-term Prophylaxis With C1-inhmentioning

confidence: 99%

Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review

Bork

Steffensen²,

Machnig³

2013

allergy asthma proc

View full text Add to dashboard Cite

Hereditary angioedema (HAE) due to C1 esterase inhibitor (HAE-C1-INH) deficiency is a rare genetic disorder presenting with recurrent episodes of skin swellings, abdominal pain attacks, and potentially fatal laryngeal edema. This study was designed to review the efficacy and safety of pasteurized, human, plasma-derived C1-INH concentrate for the treatment of patients with HAE-C1-INH. A systematic search of electronic databases up to December 2011 was performed without language or date restrictions. Two reviewers completed the study selection using predefined inclusion criteria, tabulated, and analyzed the data. The data were inappropriate for meta-analysis; thus, a qualitative synthesis was performed. We identified 89 studies (≍2000 patients) that investigated C1-INH. Replacement therapy with C1-INH significantly shortened time to onset of symptom relief in HAE attacks compared with placebo in a randomized controlled trial, and similar improvements were consistently reported in observational and descriptive studies, accompanied by improvements in patients' quality of life. C1-INH has been shown to be effective for patients receiving home therapy and short- and long-term prophylaxis. Treatment with C1-INH was generally well tolerated. Administration of C1-INH was not associated with transmission of viruses or development of autoantibodies irrespective of treatment duration. This research provides additional confirmation of the efficacy of C1-INH in the treatment and prevention of HAE attacks. C1-INH is generally safe and well tolerated and has an excellent safety record for over 25 years of clinical use.

show abstract

“…64 Short-term Prophylaxis Except for children who are undergoing surgical or diagnostic interventions in the head and neck region, short-term prophylaxis is less frequently required in children compared with adults. [65][66][67][68] Attenuated androgens such as danazol provide adequate protection when initiated 5 days before and continued 2 days after surgery with double the long-term daily dose (ie, 5 mg/kg per day; maximum of 600 mg/day). Antifibrinolytic agents (TA; see dosage above) are similarly effective for attack prevention.…”

Section: Long-term Prophylaxismentioning

confidence: 99%

Management of Hereditary Angioedema in Pediatric Patients

et al. 2007

View full text Add to dashboard Cite

Hereditary angioneurotic edema is a rare disorder caused by the congenital deficiency of C1 inhibitor. Recurring angioedematous paroxysms that most commonly involve the subcutis (eg, extremities, face, trunk, and genitals) or the submucosa (eg, intestines and larynx) are the hallmarks of hereditary angioneurotic edema. Edema formation is related to reduction or dysfunction of C1 inhibitor, and conventional therapy with antihistamines and corticosteroids is ineffective. Manifestations occur during the initial 2 decades of life, but even today there is a long delay between the onset of initial symptoms and the diagnosis of hereditary angioneurotic edema. Although a variety of reviews have been published during the last 3 decades on the general management of hereditary angioneurotic edema, little has been published regarding management of pediatric hereditary angioneurotic edema. Thus, we review our experience and published data to provide an approach to hereditary angioneurotic edema in childhood.

show abstract

Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report

Cited by 40 publications

References 26 publications

Effective Treatment of Hereditary Angioedema with Fresh Frozen Plasma in an Emergency Department

Effective Treatment of Hereditary Angioedema with Fresh Frozen Plasma in an Emergency Department

Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review

Management of Hereditary Angioedema in Pediatric Patients

Contact Info

Product

Resources

About